CAS 28860-95-9

Carbidopa

Description:

Carbidopa is a pharmaceutical compound primarily used in the treatment of Parkinson's disease and its symptoms. It functions as a dopa decarboxylase inhibitor, which prevents the conversion of levodopa to dopamine in the peripheral tissues, thereby increasing the availability of levodopa to the brain where it can be converted to dopamine. This mechanism enhances the therapeutic effects of levodopa while minimizing side effects such as nausea and vomiting. Carbidopa is often administered in combination with levodopa to improve the efficacy of treatment. The compound is characterized by its molecular formula, which includes carbon, hydrogen, nitrogen, and oxygen atoms. It is typically administered orally and is well-absorbed in the gastrointestinal tract. Carbidopa has a relatively low toxicity profile, but it may cause side effects such as dizziness, dry mouth, or dyskinesia in some patients. Its pharmacokinetics involve rapid absorption and a relatively short half-life, necessitating multiple doses throughout the day for optimal therapeutic effect.

Formula: C₁₀H₁₄N₂O₄

InChI: InChI=1S/C10H14N2O4/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6/h2-4,12-14H,5,11H2,1H3,(H,15,16)/t10-/m0/s1

InChI key: InChIKey=TZFNLOMSOLWIDK-JTQLQIEISA-N

SMILES: [C@@](CC1=CC(O)=C(O)C=C1)(C(O)=O)(NN)C

Synonyms:

• (-)-<span class="text-smallcaps">L</span>-α-Hydrazino-3,4-dihydroxy-α-methylhydrocinamic acid
• (-)-<span class="text-smallcaps">L</span>-α-Hydrazino-3,4-dihydroxy-α-methylhydrocinnamic acid monohydrate
• (-)-L-α-Hydrazino-3,4-dihydroxy-α-methylhydrocinamic acid
• (-)-L-α-Hydrazino-3,4-dihydroxy-α-methylhydrocinnamic acid monohydrate
• (2S)-2-(Aminoazaniumyl)-3-(3,4-dihydroxyphenyl)-2-methylpropanoate
• (2S)-3-(3,4-Dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid
• (S)-Carbidopa
• (αS)-α-Hydrazinyl-3,4-dihydroxy-α-methylbenzenepropanoic acid
• 1-α-(3,4-Dihydroxybenzyl)-α-hydrazinopropionic acid
• <span class="text-smallcaps">L</span>-3-(3,4-Dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid
• <span class="text-smallcaps">L</span>-Carbidopa
• <span class="text-smallcaps">L</span>-α-(3,4-Dihydroxybenzyl)-α-hydrazinopropionic acid
• <span class="text-smallcaps">L</span>-α-Hydrazino-3,4-dihydroxy-α-methylbenzenepropanoic acid
• <span class="text-smallcaps">L</span>-α-Hydrazino-α-methyl-3,4-dihydroxyphenylpropionic acid
• <span class="text-smallcaps">L</span>-α-Hydrazino-α-methyl-β-(3,4-dihydroxyphenyl)propionic acid
• <span class="text-smallcaps">L</span>-α-Methyl-α-hydrazino-3,4-dihydroxyphenylpropionic acid
• <span class="text-smallcaps">L</span>-α-Methyl-α-hydrazino-β-(3,4-dihydroxyphenyl)propionic acid
• <span class="text-smallcaps">L</span>-α-Methyl-β-(3,4-dihydroxyphenyl)-α-hydrazinopropionic acid
• <span class="text-smallcaps">L</span>-α-Methyldopahydrazine
• Benzenepropanoic acid, α-hydrazino-3,4-dihydroxy-α-methyl-, (S)-
• Benzenepropanoic acid, α-hydrazinyl-3,4-dihydroxy-α-methyl-, (αS)-
• Cabidopa
• Carbidopa
• HMD
• Hydrazino-α-methyldopa
• Hydrocinnamic acid, α-hydrazino-3,4-dihydroxy-α-methyl-, <span class="text-smallcaps">L</span>-
• Hydrocinnamic acid, α-hydrazino-3,4-dihydroxy-α-methyl-, L-
• L-3-(3,4-Dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid
• L-α-(3,4-Dihydroxybenzyl)-α-hydrazinopropionic acid
• L-α-Hydrazino-3,4-dihydroxy-α-methylbenzenepropanoic acid
• L-α-Hydrazino-α-methyl-3,4-dihydroxyphenylpropionic acid
• L-α-Hydrazino-α-methyl-β-(3,4-dihydroxyphenyl)propionic acid
• L-α-Methyl-α-hydrazino-3,4-dihydroxyphenylpropionic acid
• L-α-Methyl-α-hydrazino-β-(3,4-dihydroxyphenyl)propionic acid
• L-α-Methyl-β-(3,4-dihydroxyphenyl)-α-hydrazinopropionic acid
• L-α-Methyldopahydrazine
• Lodosin
• Lodosyn
• Mk 486
• N-Aminomethyldopa
• α-Hydrazino-α-methyl-β-(3,4-dihydroxyphenyl)propionic acid
• α-Methyldopahydrazine
• Benzenepropanoic acid, α-hydrazino-3,4-dihydroxy-α-methyl-, (αS)-
• L-alpha-Methyldopahydrazine
• 3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methyl-propanoic acid
• Tocris-0455
• 1-(Mesithylene-2-sulfonyl)-3-nitro-1,2,4-triazole
• L-alpha-Methyl-alpha-hydrazino-beta-(3,4-dihydroxyphenylpropionic acid
• Carbidopum [INN-Latin]
• alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid
• CCRIS 5093
• 3-(3,4-DIHYDROXY-PHENYL)-2-HYDRAZINO-2-METHYL-PROPIONIC ACID
• (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid hydrate (1:1)
• (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methyl-propanoic acid
• SMR000058235
• NCGC00024596-01
• (-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid
• alpha-hydrazino-3,4-dihydroxy-alpha-methyl-(S )-
• Carbidopa anhydrous
• Benzenepropanoic acid
• alpha-Methyldopahydrazine
• L-alpha-Methyl-beta-(3,4-dihydroxyphenyl)-alpha-hydrazinopropionic aci d
• alpha-HYDRAZINO-3,4-DIHYDROXY-alpha-METHYL-L-KINSON
• Hadrazino-alpha-methyldopa
• MLS000069628

Carbidopa Monohydrate

CAS: 28860-95-9, 38821-49-7

Formula: C₁₀H₁₄N₂O₄·H₂O

Purity: >98.0%(T)(HPLC)

Color and Shape: White to Light yellow powder to crystaline

Molecular weight: 244.25

Ref: 3B-C2450

3,3,3-trideuterio-2-[dideuterio-(3,4-dihydroxyphenyl)methyl]-2-hydrazinylpropanoic acid

CAS: 28860-95-9

Formula: C₁₀H₁₄N₂O₄

Purity: 99%

Color and Shape: Solid

Molecular weight: 226.2292

Ref: IN-DA00I5DW

Carbidopa

CAS: 28860-95-9

Carbidopa

Purity: ≥98%

Molecular weight: 226.23g/mol

Ref: 54-BUP13336

(S)-3-(3,4-Dihydroxyphenyl)-2-Hydrazinyl-2-Methylpropanoic Acid

CAS: 28860-95-9

(S)-3-(3,4-Dihydroxyphenyl)-2-Hydrazinyl-2-Methylpropanoic Acid

Purity: 97%

Molecular weight: 226.23g/mol

Ref: 54-OR1008689

Carbidopa

CAS: 28860-95-9

Formula: C₁₀H₁₄N₂O₄

Color and Shape: White To Off-White Solid

Molecular weight: 226.23

Ref: 4Z-C-212

Carbidopa

CAS: 28860-95-9

Carbidopa (Lodosyn) is an aromatic-L-amino-acid decarboxylase inhibitor (IC50: 29±2 μM).

Formula: C₁₀H₁₄N₂O₄

Purity: 98.01% - ≥98%

Color and Shape: Solid

Molecular weight: 226.23

Ref: TM-T6795

(S)-(-)-Carbidopa

Controlled Product

CAS: 28860-95-9

Stability Unstable in Solution
Applications (S)-(-)-Carbidopa is a peripheral decarboxylase inhibitor that is commonly used in combination with L-DOPA (D533751) for treatment of Parkinsonism. S(-)-Carbidopa ( has also been shown to prolong the elimination half-life of L-DOPA from blood plasma and skeletal muscle.
References Henry, G.M. et al.: Psychosom. Med., 38, 95 (1976); Leguire, L.E. et al.: Invest. Ophthalmol. Vis. Sci. 34, 3090 (1993); Deleu, D. et al.: Naun. Schmied. Arch. Pharmacol. 348: 576 (1993);

Formula: C₁₀H₁₄N₂O₄

Color and Shape: Neat

Molecular weight: 226.23

Ref: TR-C175985